Geneseq Biosciences is a biotechnology company founded in 2018 in Melbourne, Australia, dedicated to advancing the early and accurate diagnosis of cancer.
Guided by a deep understanding of cancer biology, Geneseq’s R&D pipeline combines our international expertise in in-vitro diagnostic (IVD) assay design, scalable bioinformatics, and regulatory requirements. This allows us to develop products and services that enable early, accurate cancer diagnosis, predict treatment responses, and monitor patient outcomes.
Melaseq™, our flagship technology, is a clinically validated, NATA-accredited next-generation genomic test. It harnesses the latest insights in melanoma biology, to provide clinicians with a powerful new tool for detecting and diagnosing the deadliest form of skin cancer.
We use cookies to ensure that we give you the best experience on our site.Ok
